Publication Name	World Journal of Nephrology
Manuscript ID	121881
Country	Greece

Category	Urology & Nephrology
Manuscript Type	Correspondence
Article Title	Letter to the Editor: Finerenone and proteinuria in diabetic kidney disease
Manuscript Source	Unsolicited Manuscript
All Author List	Vaia D Raikou and Sotiris Gavriil
Funding Agency and Grant Number
Corresponding Author	Vaia D Raikou, Chief, PhD, Department of Nephrology, Doctors’ General Clinic, 26 Kefallinias, Athens 11257, Greece. vraikou@med.uoa.gr
Key Words	Diabetic nephropathy; Proteinuria; Kidney inflammation; Finerenone; Cardiovascular events
Core Tip	Diabetic nephropathy is mainly characterized by proteinuria, which contributes to renal progression and cardiovascular complications. Finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, can reduce proteinuria with a dependance on initial baseline proteinuria, despite its effect may be disproportional and variant. More factors including genetics or epigenetics may be involved in diabetic kidney pathology, because of which proteinuria persists.
Citation	Raikou VD, Gavriil S. Letter to the Editor: Finerenone and proteinuria in diabetic kidney disease. World J Nephrol 2026; In press

Received	2026-04-07 01:49
Peer-Review Started	2026-04-07 01:50
First Decision by Editorial Office Director	2026-04-13 09:25
Return for Revision	2026-04-13 09:25
Revised	2026-04-27 21:04
Publication Fee Transferred
Second Decision by Editor	2026-05-13 02:45
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-05-13 08:27
Articles in Press	2026-05-13 08:27
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2220-6124 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com